Related Experiment Video
Updated: May 20, 2026

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Nanotechnology and therapeutic delivery: a drug regulation perspective
Nakissa Sadrieh1, Katherine M Tyner
1Center for Drug Evaluation & Research, US FDA, 10903 New Hampshire Ave., Silver Spring, MD 20993, USA.
Abstract:
Nanotechnology is expected to contribute to the therapeutic delivery field in the coming decade. Although the US FDA has multiple guidance documents in place to deal with novel drug products, nanoparticles may produce issues that have not been previously encountered with small drug molecules. This regulatory focus highlights some current guidance documents and thinking of the FDA as applied to nanoparticles used for therapeutic delivery.
Related Concept Videos
Drug Regulation
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Modified-Release Drug Delivery Systems: Classification
Drug Control Governance: Regulatory Bodies and Their Impact
